Peter Greenleaf, MBA Picture
<p><strong>Current Boards</strong></p> <ul> <li>Aurinia Pharmaceuticals, Inc. (CEO-public)</li> <li>Revolo Biotherapeutics Ltd (Chairman-private)</li> </ul> <p><strong>Prior Boards</strong></p> <ul> <li>Valenza Bio (private)</li> <li>Antares Pharma Inc (public)</li> <li>Biodelivery Sciences International Inc (Chairman-public)</li> <li>Avalo Therapeutics Inc (public; formerly Cerecor Pharmaceuticals, Inc.)</li> <li>Kiora Pharmaceuticals Inc (public; formerly EyeGate Pharmaceuticals, Inc.)</li> <li>Sucampo Pharmaceuticals Inc (Chairman-public)</li> <li>Synlogic Inc (public; formerly Mirna Therapeutics, Inc.)</li> <li>Savara Inc (public; formerly Mast Therapeutics, Inc.)</li> <li>OS Therapies (private)</li> <li>Histogenics Corp (private)</li> <li>Corridor Pharmaceuticals Inc (private)</li> <li>Melinta Therapeutics Inc (private; formerly Rib-X Pharmaceuticals, Inc.)</li> <li>LigoCyte Pharmaceuticals Inc (private)</li> <li>Maryland Venture Fund Authority (MVFA) (government)</li> <li>The University of Maryland Baltimore Campus (board of trustees)</li> <li>BIO (board member)</li> <li>PhRMA (board member)</li> </ul>

Peter Greenleaf, MBA

Director, President and CEO

Peter Greenleaf currently serves as the Chief Executive Officer and member of the Board of Directors of Aurinia.

From March 2018 to April 2019, Peter served as the CEO of Cerecor Pharmaceuticals, Inc. (now Avalo Therapeutics, Inc.). From March 2014 to February 2018, Peter served as CEO and Chairman of Sucampo Pharmaceuticals, Inc. Sucampo was focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide and was sold in February 2018 to UK pharmaceutical company, Mallinckrodt PLC. From June 2013 to March 2014, Peter served as CEO and a member of the Board of Directors of Histogenics Corporation, a regenerative medicine company. From 2006 to 2013, he was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. From January 2010 to June 2013, Peter also served as President of MedImmune Ventures, a wholly-owned venture capital fund within the AstraZeneca Group.

Prior to serving as President of MedImmune, Peter was Senior Vice President, Commercial Operations of the company, responsible for its commercial, corporate development, and strategy functions. He has also held senior commercial roles at Centocor, Inc. (now Jansen Biotechnology, Johnson & Johnson) from 1998 to 2006 and at Boehringer Mannheim (now Roche Holdings) from 1996 to 1998.

Peter previously partnered with Governor Martin O’Malley to chair the Maryland Venture Fund Authority, whose vision was to oversee the implementation of Invest Maryland, a public-private partnership to spur venture capital investment in the state. In addition, he has extensive public and private board experience and has served in leadership roles on both BIO and PhRMA throughout the years. Peter earned an MBA from St. Joseph’s University and a B.S. from Western Connecticut State University.

Peter’s significant executive management, leadership, corporate development, and commercial operations experience in the biopharmaceutical industry enables him to provide valuable insight to our Board of Directors.

Back to top